Stocks - Wall Street Leaps as Gilead Upstages Weak GDP. Dow Rises 400 Points

Investing.com

Published Apr 29, 2020 09:35AM ET

Updated Apr 29, 2020 10:07AM ET

By Geoffrey Smith 

Investing.com -- U.S. stock markets opened sharply higher on Wednesday as positive news from a trial of Gilead Science's (NASDAQ:GILD) experimental drug remdesivir upstaged the worst U.S. GDP report in nearly 12 years. 

By 10 AM ET (1400 GMT), the Dow Jones Industrial Average was up 465 points, or 1.9%, at 24,567 points. The S&P 500 was up 2.2% and the Nasdaq Composite was up 2.6%.

The Nasdaq (NASDAQ:NDAQ) was helped by a strong contribution from Alphabet (NASDAQ:GOOGL) stock, which rose 7.8% after better-than-expected first-quarter results. Chief financial officer Ruth Porat told an analyst call that there had been no further big drops in advertising revenue in April after a sharp fall in March. YouTube, one of the company's biggest cash cows, raked in $4 billion in the quarter, a rise of 33% from a year earlier.

Earlier, Gilead had said that a stage 1 trial of remdesivir had shown that the retroviral drug helped improve symptoms in Covid-19 patients who were given the drug early. The effect on those who were given it at a later stage were not as positive.  

Interest in Gilead's drug has been high as there are currently no approved treatments or preventive vaccines for Covid-19, something that analysts say leaves the global economy vulnerable to secondary waves of infection over the next year or two. Gilead stock rose 5.9% at opening to within a couple of percent of the two-year high it earlier in April.

The prospect of progress in finding a cure lifted airline and cruise stocks disproportionately, on the perception that they have most to gain from the boost to public confidence from having a readily available treatment for the disease.

The same reasoning also lifted the price of crude oil. U.S. crude futures extended gains to be up 24.5% at $15.38 a barrel by 10 AM ET. The international Brent contract rose 7.2% to $24.38.

The news deflected attention away from the weakest report for U.S. gross domestic product in almost 12 years. The economy shrank by an annualized 4.8% in the first quarter, even more than expected by analysts, as personal consumption slumped in response to mass layoffs as state authorities issued a barrage of lockdown orders through March.

The collapse was also reflected in a wider-than-expected loss of $1.7 billion for Boeing. Boeing (NYSE:BA) stock still rose 5.7% after Reuters reported that the company is preparing to cut around 10% of its workforce as it brings production down into line with a much lower level of expected future demand.

One underperformer was Advanced Micro Devices (NASDAQ:AMD) stock, which fell 3.5% after the chipmaker lowered the bottom end of its guidance for 2020 sales growth to 20% from 28% previously. 

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes